May 24, 2026 12:24 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Honoured to visit the Missionaries of Charity today, says Rubio after Kolkata visit, arrives in Delhi | Marco Rubio's India visit begins in Kolkata: Trade, defence and Quad talks take centre stage | Third fuel price hike in India in 10 days: Here’s what you’ll pay now | Big twist in RG Kar case! Calcutta HC orders fresh probe into evidence destruction allegations | Pulwama mastermind Hamza Burhan shot dead in PoK by unknown gunmen: Reports | NIA arrests Kolkata man for spying for Pakistan intelligence network | Cockroach Janta Party X handle withheld! Founder Abhijeet Dipke launches comeback account | Bengal govt makes Vande Mataram compulsory in all madrasas, extends school directive | RBI on alert! Interest rate hike may be coming as rupee crashes to fresh low | Big relief for Maharashtra employees! Fadnavis govt hikes DA to 60%
Pfizer
WIKIMEDIA COMMONS

Pfizer to only get half of COVID-19 vaccines out this year due to logistics: Reports

| @indiablooms | Dec 04, 2020, at 02:45 pm

Washington/Sputnik: US drug giant Pfizer expects to ship just about half of the COVID-19 vaccines it originally planned for this year because of supply-chain problems, although it still expects to roll out more than a billion doses in 2021, the Wall Street Journal reported.

Scaling up the raw material supply chain took longer than expected, a Pfizer spokesperson told the newspaper on Thursday.

The outcome of the clinical trial, the spokesperson added, was somewhat later than the initial projection.

New York-headquartered Pfizer and Germany-based partner BioNTech SE had hoped to roll out 100 million vaccines world-wide by the end of this year, a plan that has now been reduced to 50 million, the report said.

The United Kingdom on Wednesday granted emergency-use authorization for the vaccine, becoming the first Western country to start administering doses.

The two-shot Pfizer vaccine is also being reviewed by the US Food and Drug Administration, where a similar authorization could come later this month and a rollout before the end of the year. The US regulator also is considering a vaccine developed by Cambridge, Mass.-based Moderna Inc. that could begin shipping before Christmas.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.